Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Beta-cell recovery to counter diabetes

Obiettivo

Globally 8,75M people with T1D rely only on insulin administration to manage the symptoms of their disease. The treatment is complex since it requires injecting insulin (2-4 times/day) and adhering to a restrictive lifestyle (e.g. following a strict diet) reducing patient QoL. Even with insulin, less than 20% of patients achieve their target glucose level, which eventually leads to vascular complications (e.g. stroke, renal disease) reducing life expectancy by 10-15 years.
DiogenX aims to withdraw insulin dependency and cure T1D by regenerating pancreatic beta-cell to allow autonomous insulin release in response to blood glucose levels increases.
We expect to out-license our drug to a pharma company, some of them have already manifested their interest and invested in the capital of DiogenX. This may materialize as soon as clinical proof of principle is demonstrated in humans, which will be reached in 2026 with the proceeds from Series A to be raised in 2023, which is 80% secured.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-EIC-2023-ACCELERATOR-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

DIOGENX SAS
Contributo netto dell'UE
€ 2 500 000,00
Indirizzo
180 AVENUE DU PRADO
13008 Marseille
Francia
PMI
Sì
Regione
Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Bouches-du-Rhône
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 5 673 000,00